ABSTRACT
In a randomized controlled clinical trial of hyperbaric oxygen in the radiotherapy of carcinoma of the bladder a total of 241 cases were contributed by four radiotherapy centres in the United Kingdom. In this trial where in each centre identical radiotherapy was employed for both oxygen and air cases, no benefit was shown with the use of hyperbaric oxygen.
Subject(s)
Hyperbaric Oxygenation , Urinary Bladder Neoplasms/radiotherapy , Air , Clinical Trials as Topic , Humans , Radiotherapy Dosage , Random Allocation , Urinary Bladder Neoplasms/mortalityABSTRACT
In a randomized controlled clinical trial of hyperbaric oxygen in the radiotherapy of advanced carcinoma of the uterine cervix a total of 320 cases were contributed by four radiotherapy centres in the United Kingdom. The use of hyperbaric oxygen resulted in improved local control and survival. The benefit was greatest in patients under the age of 55 who presented with stage III disease. There was a slight increase in radiation morbidity but it seemed that the benefit of hyperbaric oxygen outweighed this increase in morbidity and that there was a true improvement in the therapeutic ratio.
Subject(s)
Hyperbaric Oxygenation , Uterine Cervical Neoplasms/radiotherapy , Adult , Age Factors , Aged , Carcinoma, Squamous Cell/radiotherapy , Clinical Trials as Topic , Female , Humans , Middle Aged , Neoplasm Recurrence, Local , Neoplasm Staging , Random Allocation , Uterine Cervical Neoplasms/pathologyABSTRACT
For 12 years randomised clinical trials have been run at Portsmouth in collaboration with the Medical Research Council's Working Party on radiotherapy and high pressure oxygen to determine the survival rate of patients treated by megavoltage radiotherapy in high pressure oxygen (HPO) compared with those treated in air at atmospheric pressure. Five hundred and five patients have been included, 280 with carcinoma bronchus, 163 with carcinoma bladder and 62 with carcinoma cervix stage III. With conventional small fraction daily radiotherapy, the use of HPO has not improved survival in carcinoma of the bronchus and of the bladder. When six fractions of 600 rad maximum tissue dose are given in HPO, some improved survival is shown in carcinoma of the bronchus and of the cervix compared with the same dose in the air series. In the cervix, the survival rate in HPO is almost the same as that of a retrospective series treated by an intrauterine radium tube followed by 6000 rad central depth dose to the whole true pelvis in air. Large fraction radiotherapy has not given improved survival when using adjuvant HPO in carcinoma of the bladder. The bladder trial has now been abandoned.
